An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti‐Angiogenic Agents for Therapy: A Case Report

An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti‐Angiogenic Agents for Therapy: A Case Report

ABSTRACT Background Although the presence of Kirsten murine sarcoma virus (KRAS) mutations predicts a failure of non‐small cell carcinoma (NSCLC) patients to benefit from epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitor (TKI) therapy it may be more sensitive to programmed combinatio...

Full description

Saved in:
Bibliographic Details
Main Authors: Li Wang, Jiaqi Wu, Ping Shao, Wuping Bao, Lin Mao, Zhendong Pan, Aihua Bao, Min Zhang, Zhenghua Wu, Guorong Fan
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Cancer Reports
Subjects:
anti‐angiogenic agents
camrelizumab
case report
KRAS mutations
lung adenocarcinoma
Online Access:https://doi.org/10.1002/cnr2.70186
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://doi.org/10.1002/cnr2.70186

Similar Items